


Cytométrie en flux et masse suspecte en hématologie

Valéry Daubie

La cytométrie

- Cellules en suspension < sang, moelle osseuse, liquides (LCR, LBA, ...), ganglion
- Marquage anticorps anti-CD + fluorochrome


Fluorochrome	Excitation	Emission
 FITC	494-517	518
 PE	470-570	576
 PerCP	470-570	670
 APC	650	660-680




La cytométrie

- Cellules en suspension < sang, moelle osseuse, liquides (LCR, LBA, ...), ganglion
- Marquage anticorps anti-CD + fluorochrome


Fluorochrome	Excitation	Emission
 FITC	494-517	518
 PE	470-570	576
 PerCP	470-570	670
 APC	650	660-680





La cytométrie





La cytométrie





La cytométrie





La cytométrie




La cytométrie





La cytométrie




La cytométrie




La cytométrie




Application: la LLC-B




CD5 A750






Application: la LLC-B



CD5 A750



Application: la LLC-B



WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

Steven H. Swerdlow, Elias Campo, Nancy Lee Harris, Elaine S. Jaffe, Stefano A. Pileri, Harald Stein, Jurgen Thiele, Daniel A. Arber, Robert P. Hasserjian, Michelle M. Le Beau, Attilio Orazi, Reiner Siebert





Fig. 1.05 Antigen expression at various stages of normal myeloid differentiation

Cas clinique n°1



De l'intérêt du « multi-canaux »

Septembre 2019

Depuis de nombreuses années, au moins depuis le début des années 2000, le patient est connu avec une leucocytose augmentée aux dépens des lignées neutrophiliques et lymphocytaires.

Le bilan biologique effectué en date du 9/10/2019 montre une hyperleucocytose avec 21380 él/mm^3 dont 9490 lymphocytes. Parmi ceux-ci, il existe 6631 cellules dont l'immunophénotypage est compatible avec une leucémie lymphoïde chronique B. Il n'y a pas d'anémie, pas de thrombopénie, pas de stigmate d'hémolyse, pas de syndrome inflammatoire, pas d'élévation enzymatique suspecte, pas de pic à l'électrophorèse des protéines.

En conclusion :

Le patient présente une leucémie lymphoïde chronique B au stade A selon la classification de Binet.

Présence d'une population de lymphocytes B CD19+ CD20+ CD22faible+ CD5+ CD10- CD23+ CD38- CD43++ CD79b- CD81faible+ CD200+ et monoclonale kappa à 96% parmi les lymphocytes B soit 6631 cellules / μL compatible avec une LLC-B.

Pour l'instant, une simple surveillance est préconisée.




Un traitement pourrait être indiqué :

- Si les lymphocytes doublent en moins de 6 mois.
- Si le patient développe une anémie à moins de 10 g/dL ou une thrombopénie à moins de 100000 él/mm^3 .
- Si le patient développe des symptômes systémiques (amaigrissement, sudation...).
- S'il développe des adénopathies gênantes et/ou une splénomégalie.






Août 2022

GR	4.48 x10 ⁶ /mm ³
HB	13.3 g/dL
HCT	39.2 %
MCV	87.5 µm ³
MCH	29.7 pg
MCHC	33.9 g/dL
RDW	14.3 %
PLT	218 x10 ³ /mm ³
MPV	10.6 µm ³
P-MPV	8.5 fL
RETIC %	1.55 %
RET VA	69.4 x10 ³ /mm ³
GB	77.66 x10 ³ /mm ³
GB_CONF	Formule réalisée au m/
PMN	*7.1 %
PMN VA	*5.38 x10 ³ /mm ³
PMN MANU	7.0 %
PMN MANU VA	5.44 x10 ³ /mm ³
LYM Ctrl F	90.5 %
LYM VA	*70.28 x10 ³ /mm ³
LYM VA	70.28 x10 ³ /mm ³
MONO	1.0 %
MONO VA	0.78 x10 ³ /mm ³
EOS	1.5 %
EOS VA	1.16 x10 ³ /mm ³
BASO	0.0 %
BASO VA	0.00 x10 ³ /mm ³
IGF	1.1 %

Août 2022

















Août 2022



Présence d'une population de lymphocytes B CD19+ CD20+ CD22faible+ CD5+ CD10- CD38-

Août 2022












Morphologiquement, on visualise 30% de prolymphocytes parmi les lymphocytes et la présence de lymphocytes de plus grande taille, avec cytoplasme basophile, évoquant une transformation lymphomateuse ou une transformation prolymphocytaire.




Cas clinique n°II

de Lagardère (1857)















CD19.AA700



Cas clinique n°III



Une aiguille dans un botte de foin


A 55-year-old man with a 1-month history of asthenia, right hypochondrial pain, and weight loss was referred to the emergency department for hepatic mass evaluation.

Abdominal computed tomography scan revealed a large necrotic mass in the liver, a second necrotic mass adjacent to the superior mesenteric vessels, and numerous subdiaphragmatic lymph nodes (aorta, right kidney, retro-crural, mesenteric, iliac, and inguinal)

→ Biopsie inguinale

A 55-year-old man with a 1-month history of asthenia, right hypochondrial pain, and weight loss was referred to the emergency department for hepatic mass evaluation.

Abdominal computed tomography scan revealed a large necrotic mass in the liver, a second necrotic mass adjacent to the superior mesenteric vessels, and numerous subdiaphragmatic lymph nodes (aorta, right kidney, retro-crural, mesenteric, iliac, and inguinal)



cells were positive for common leukocyte antigen (CLA), CD20, and CD30 and negative for anaplastic lymphoma kinase (Figure 1D-F).


Epstein-Barr virus-encoded small RNA was negative.

Histological

examination revealed infiltration by sheets of large lymphoid cells displaying irregularly shaped nuclei with macronucleoli and moderately abundant, finely granular cytoplasm

A 55-year-old man with a 1-month history of asthenia, right hypochondrial pain, and weight loss was referred to the emergency department for hepatic mass evaluation.

Abdominal computed tomography scan revealed a large necrotic mass in the liver, a second necrotic mass adjacent to the superior mesenteric vessels, and numerous subdiaphragmatic lymph nodes (aorta, right kidney, retro-crural, mesenteric, iliac, and inguinal)



cells were positive for common leukocyte antigen (CLA), CD20, and CD30 and negative for anaplastic lymphoma kinase (Figure 1D-F).

Epstein-Barr virus-encoded small RNA was negative.

Histological

examination revealed infiltration by sheets of large lymphoid cells displaying irregularly shaped nuclei with macronucleoli and moderately abundant, finely granular cytoplasm




Diffuse large B-cell lymphoma (DLBCL)

A 55-year-old man with a 1-month history of asthenia, right hypochondrial pain, and weight loss was referred to the emergency department for hepatic mass evaluation.

Abdominal computed tomography scan revealed a large necrotic mass in the liver, a second necrotic mass adjacent to the superior mesenteric vessels, and numerous subdiaphragmatic lymph nodes (aorta, right kidney, retro-crural, mesenteric, iliac, and inguinal)

Au labo...




Inguinal lymph node biopsy imprint showing a heterogeneous background containing (A) eosinophils and (B, 1) large cells with various nucleocytoplasmic ratios, occasionally irregular nuclear contour, dispersed and delicately condensed mixed chromatin, multiple prominent nucleoli and deeply basophilic cytoplasm and (B, 2) scattered cells with sternbergoid features and decreased cytoplasmic basophilia

A 55-year-old man with a 1-month history of asthenia, right hypochondrial pain, and weight loss was referred to the emergency department for hepatic mass evaluation.


Abdominal computed tomography scan revealed a large necrotic mass in the liver, a second necrotic mass adjacent to the superior mesenteric vessels, and numerous subdiaphragmatic lymph nodes (aorta, right kidney, retro-crural, mesenteric, iliac, and inguinal)

Au labo...



Flow cytometry charts showing the presence of two cell populations with different immunophenotypes: a population with high side scatter (SSC), CD19+, CD20+, CD22+, CD15+dim, CD30+dim, CD45+ cells (blue population) and a few CD19-, CD20-, CD15+dim, CD30+bright, CD45- cells (red population).

Cas clinique n°VI



Il n'y a pire eau que l'eau qui dort

2018

- Femme – 45 ans
- Nodules sous cutanés (abdomen et membres inférieurs)
- Régressions spontanées



2015

2018

- Femme – 45 ans
- Nodules sous cutanés (abdomen et membres inférieurs)
- Régressions spontanées < 2015




2015

2018

- Femme – 45 ans
- Nodules sous cutanés (abdomen et membres inférieurs)
- Régressions spontanées < 2015

Cutaneous infiltration that involves both the dermis and the adipose panniculitic tissue.

The epidermis shows marked oedema with basal vacuolization and polymorphic inflammatory reaction, in the absence of tumour infiltration



Biopsie (HE)

2015


2018

- Femme – 45 ans
- Nodules sous cutanés (abdomen et membres inférieurs)
- Régressions spontanées < 2015

Median to large size population of neoplastic lymphocytes, with frequent pleomorphic features.

In the dermis these cells show angiotropism with some focus of thrombosis.

In the panniculitic tissue they are located surrounding the adipose tissue cells with a panniculitic-like pattern, frequently associated with destruction of the adipose tissue and a granulomatosis reaction



Biopsie (HE)

2015

2018

Cytométrie

population:

- *T-cell CD3+ CD45+, phénotype **CD5-** CD7- CD4- CD8- TCR $\gamma\delta$*
- *with cytotoxic/killer marker-associated expression: CD56+, TIA1+, Granzyme B+*
- *in addition: EBER-, CD34-, CD123-, Tdt-, and CD20-*

... au milieu d'un background de lymphocytes T réactionnels CD4+ ou CD8+...

2015

2018

Cytométrie

population:

- *T-cell CD3+ CD45+, phénotype **CD5-** CD7- CD4- CD8- TCR $\gamma\delta$*
- *with cytotoxic/killer marker-associated expression: CD56+, TIA1+, Granzyme B+*
- *in addition: EBER-, CD34-, CD123-, Tdt-, and CD20-*

Table 14.05 Differential diagnosis of neoplasms expressing T-cell and NK-cell markers with frequent cutaneous involvement

Disease	Clinical features	CD3	CD4	CD8	Cytotoxic molecules ^a	CD56	EBV	TR genes	Lineage
SPTCL	Tumours (extremities and trunk)	+	–	+	+	–	–	R	T-cell
PCGD-TCL	Tumours, plaques, ulcerated nodules	+	–	–/+	+	+	–	R	T-cell
Extranodal NK/TCL	Nodules, tumours	+	–	–/+	+	+	+	G	NK-cell, sometimes T-cell
Primary C-ALCL	Superficial nodules with epidermal involvement	+	+	–	+	–	–	R	T-cell
Mycosis fungoides	Patches, plaques, tumours late in course	+	+	–	–	–	–	R	T-cell
Blastic PDC neoplasm	Nodules, tumours	–	+	–	–	+	–	G	Precursor of PDC
C-ALCL, cutaneous anaplastic large cell lymphoma; G, in germline configuration; PCGD-TCL, primary cutaneous gamma delta T-cell lymphoma; PDC, plasmacytoid dendritic cell; R, rearranged; SPTCL, subcutaneous panniculitis-like T-cell lymphoma; TCL, T-cell lymphoma; TR, T-cell receptor.									
^a Cytotoxic granule-associated protein(s) TIA1, granzyme B, and/or perforin.									
^b Marked variation in T-cell antigens, including frequent antigen loss of CD3, CD4, CD8									

2015

2018

Cytométrie

population:

- *T-cell CD3+ CD45+, phénotype **CD5-** CD7- CD4- CD8- TCR $\gamma\delta$*
- *with cytotoxic/killer marker-associated expression: CD56+, TIA1+, Granzyme B+*
- *in addition: EBER-, CD34-, CD123-, Tdt-, and CD20-*



Table 14.05 Differential diagnosis of neoplasms expressing T-cell and NK-cell markers with frequent cutaneous involvement

Disease	Clinical features	CD3	CD4	CD8	Cytotoxic molecules ^a	CD56	EBV	TR genes	Lineage
SPTCL	Tumours (extremities and trunk)	+	-	+	+	-	-	R	T-cell
PCGD-TCL	Tumours, plaques, ulcerated nodules	+	-	-/+	+	+	-	R	T-cell
Extranodal NK/TCL	Nodules, tumours	+	-	-/+	+	+	+	G	NK-cell, sometimes T-cell
Primary C-ALCL	<i>compatible with infiltration by a primary cutaneous gamma-delta T cell lymphoma, pending confirmation of TCR$\gamma\delta$ expression and rearrangement.</i>								
Mycosis fungoides	Patches, plaques, tumours late in course	+	+	-	-	-	-	R	T-cell
Blastic PDC neoplasm	Nodules, tumours	-	+	-	-	+	-	G	Precursor of PDC
C-ALCL, cutaneous anaplastic large cell lymphoma; G, in germline configuration; PCGD-TCL, primary cutaneous gamma delta T-cell lymphoma; PDC, plasmacytoid dendritic cell; R, rearranged; SPTCL, subcutaneous panniculitis-like T-cell lymphoma; TCL, T-cell lymphoma; TR, T-cell receptor.									
^a Cytotoxic granule-associated protein(s) TIA1, granzyme B, and/or perforin.									
^b Marked variation in T-cell antigens, including frequent antigen loss of CD3, CD4, CD8									

2015

2018

- Anticorps anti- δ (TCR $\gamma\delta$) – MD Anderson Cancer Center (USA)



➡ Cellules lymphomateuses peri-vasculaires: positives pour anti- δ (TCR $\gamma\delta$)

2015

2018

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

14 Mature T- and NK-cell neoplasms

14 Mature T- and NK-cell neoplasms	345
T-cell prolymphocytic leukaemia	346
T-cell large granular lymphocytic leukaemia	348
Chronic lymphoproliferative disorder of NK cells	351
Aggressive NK-cell leukaemia	353
EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood	355
Systemic EBV+ T-cell lymphoma of childhood	355
Chronic active EBV infection of T- and NK-cell type, systemic form	358
Hydroa vacciniforme-like lymphoproliferative disorder	360
Severe mosquito bite allergy	362
Adult T-cell leukaemia/lymphoma	363
Extranodal NK/T-cell lymphoma, nasal type	368
Intestinal T-cell lymphoma	372
Enteropathy-associated T-cell lymphoma	372
Monomorphic epitheliotropic intestinal T-cell lymphoma	377
Intestinal T-cell lymphoma, NOS	378
Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract	379
Hepatosplenic T-cell lymphoma	381
Subcutaneous panniculitis-like T-cell lymphoma	383
Mycosis fungoides	385
Sézary syndrome	390
Primary cutaneous CD30-positive T-cell lymphoproliferative disorders	392
Lymphomatoid papulosis	392
Primary cutaneous anaplastic large cell lymphoma	395
Primary cutaneous peripheral T-cell lymphomas, rare subtypes	397
Introduction	397
Primary cutaneous gamma delta T-cell lymphoma	397
Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma	399
Primary cutaneous acral CD8-positive T-cell lymphoma	400
Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder	401
Peripheral T-cell lymphoma, NOS	403
Angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular helper (TFH) cell origin	407
Angioimmunoblastic T-cell lymphoma	408
Follicular T-cell lymphoma	411
Nodal peripheral T-cell lymphoma with TFH phenotype	412
Anaplastic large cell lymphoma, ALK-positive	413
Anaplastic large cell lymphoma, ALK-negative	418
Breast implant-associated anaplastic large cell lymphoma	421

2015

2018

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

14 Mature T- and NK-cell neoplasms

14 Mature T- and NK-cell neoplasms	345
T-cell prolymphocytic leukaemia	346
T-cell large granular lymphocytic leukaemia	348
Chronic lymphoproliferative disorder of NK cells	351
Aggressive NK-cell leukaemia	353
EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood	355
Systemic EBV+ T-cell lymphoma of childhood	355
Chronic active EBV infection of T- and NK-cell type, systemic form	358
Hydroa vacciniforme-like lymphoproliferative disorder	360
Severe mosquito bite allergy	362
Adult T-cell leukaemia/lymphoma	363
Extranodal NK/T-cell lymphoma, nasal type	368
Intestinal T-cell lymphoma	372
Enteropathy-associated T-cell lymphoma	372
Monomorphic epitheliotropic intestinal T-cell lymphoma	377
Intestinal T-cell lymphoma, NOS	378
Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract	379
Hepatosplenic T-cell lymphoma	381
Subcutaneous panniculitis-like T-cell lymphoma	383
Mycosis fungoides	385
Sézary syndrome	390
Primary cutaneous CD30-positive T-cell lymphoproliferative disorders	392
Lymphomatoid papulosis	392
Primary cutaneous anaplastic large cell lymphoma	395
Primary cutaneous peripheral T-cell lymphomas, rare subtypes	397
Introduction	397
Primary cutan	
Primary cutan	
epidermot	
Primary cutan	
Primary cutaneous CD4+ anaplastic large cell lymphoproliferative disorder	401
Peripheral T-cell lymphoma, NOS	403
Angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular helper (TFH) cell origin	407
Angioimmunoblastic T-cell lymphoma	408
Follicular T-cell lymphoma	411
Nodal peripheral T-cell lymphoma with TFH phenotype	412
Anaplastic large cell lymphoma, ALK-positive	413
Anaplastic large cell lymphoma, ALK-negative	418
Breast implant-associated anaplastic large cell lymphoma	421

Primary cutaneous peripheral T-cell lymphomas,
rare subtypes

2015

2018

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

14 Mature T- and NK-cell neoplasms

14 Mature T- and NK-cell neoplasms	345
T-cell prolymphocytic leukaemia	346
T-cell large granular lymphocytic leukaemia	348
Chronic lymphoproliferative disorder of NK cells	351
Aggressive NK-cell leukaemia	353
EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood	355
Systemic EBV+ T-cell lymphoma of childhood	355
Chronic active EBV infection of T- and NK-cell type, systemic form	358
Hydroa vacciniforme-like lymphoproliferative disorder	360
Severe mosquito bite allergy	362
Adult T-cell leukaemia/lymphoma	363
Extranodal NK/T-cell lymphoma, nasal type	368
Intestinal T-cell lymphoma	372
Enteropathy-associated T-cell lymphoma	372
Monomorphic epitheliotropic intestinal T-cell lymphoma	377
Intestinal T-cell lymphoma, NOS	378
Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract	379
Hepatosplenic T-cell lymphoma	381
Subcutaneous panniculitis-like T-cell lymphoma	383
Mycosis fungoides	385
Sézary syndrome	390
Primary cutaneous CD30-positive T-cell lymphoproliferative disorders	392
Lymphomatoid papulosis	392
Primary cutaneous anaplastic large cell lymphoma	395
Primary cutaneous peripheral T-cell lymphomas, rare subtypes	397
Introduction	397
Primary cutan	
Primary cutan	
epidermot	
Primary cutan	
Primary cutaneous CD4+ anaplastic large cell lymphoproliferative disorder	401
Peripheral T-cell lymphoma, NOS	403
Angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular helper (TFH) cell origin	407
Angioimmunoblastic T-cell lymphoma	408
Follicular T-cell lymphoma	411
Nodal peripheral T-cell lymphoma with TFH phenotype	412
Anaplastic large cell lymphoma, ALK-positive	413
Anaplastic large cell lymphoma, ALK-negative	418
Breast implant-associated anaplastic large cell lymphoma	421

Primary cutaneous peripheral T-cell lymphomas, rare subtypes

Primary cutaneous gamma delta T–cell lymphoma

Definition

Primary cutaneous gamma delta T–cell lymphoma (PCGD–TCL) is a lymphoma, involving primarily the skin, composed of a clonal proliferation of mature, activated gamma delta T cells with a cytotoxic phenotype.

Prognosis and predictive factors

PCGD–TCLs are usually resistant to multiagent chemotherapy and/or radiation and have a poor prognosis, with a median survival of approximately 15 months {4031,4321}. Patients with subcutaneous fat involvement tend to have a more unfavourable prognosis than do patients with epidermal or dermal disease only {4031}.

2015

2018

2020

Two years later, the patient was hospitalized for recurrent fever, cough, and severe dyspnea.



2015

2018

2020

Two years later, the patient was hospitalized for recurrent fever, cough, and severe dyspnea.




➡ PCR SARS-CoV-2 négative!

2015

2018

2020




➡ Lavage broncho-alvéolaire

2015



2018

2020





→ Lavage broncho-alvéolaire

SARS-CoV-2 négatif!



T-cell CD3+ CD45+, phénotype CD5- CD7- CD4- CD8- TCR $\gamma\delta$



Perspectives



Immunophénotypage des leucémies :
Analyses en composantes principales
comme aide à la décision automatisée

Valéry Daubie

- Régression linéaire
 - Fonction multivariée
 - ACP
- } Bases mathématiques de l'A.I.

Perspectives



Immunophénotypage des leucémies :
Analyses en composantes principales
comme aide à la décision automatisée

Valéry Daubie

- Régression linéaire
- Fonction multivariée
- ACP

} Bases mathématiques de l'A.I.

REVIEW

ADVANCED
INTELLIGENT
SYSTEMS

www.advintellsyst.com



Machine-Learning-Assisted Intelligent Imaging Flow
Cytometry: A Review

Perspectives



Immunophénotypage des leucémies :
Analyses en composantes principales
comme aide à la décision automatisée

Valéry Daubie




Avalanche Photodiode.
The DxFLEx flow cytometer uses Avalanche Photodiode detectors instead of PMTs. The low electronic noise contributes to the resolution capabilities of the instrument.

Perspectives




Immunophénotypage des leucémies :
Analyses en composantes principales
comme aide à la décision automatisée

Valéry Daubie



Avalanche Photodiode.
The DxFLEX flow cytometer uses Avalanche Photodiode detectors instead of PMTs. The low electronic noise contributes to the resolution capabilities of the instrument.



Perspectives





Immunophénotypage des leucémies :
Analyses en composantes principales
comme aide à la décision automatisée

Valéry Daubie

- Régression linéaire
- Fonction multivariée
- ACP

Bases mathématiques de l'A.I.

Découverte de “nouveaux profils”?



Perspectives




Immunophénotypage des leucémies :
Analyses en composantes principales
comme aide à la décision automatisée

Valéry Daubie

- Régression linéaire
- Fonction multivariée
- ACP

Bases mathématiques de l'A.I.

Découverte de “nouveaux profils”?



Evénements “rares”

Perspectives



Immunophénotypage des leucémies :
Analyses en composantes principales
comme aide à la décision automatisée


Valéry Daubie

- Régression linéaire
- Fonction multivariée
- ACP

Bases mathématiques de l'A.I.

Découverte de “nouveaux profils”?

Marqueurs d'évolution et d'agressivité




Evénements “rares”

Perspectives



AI
Machine learning
Big Data

Le macroscopique



Evénements “rares”



Le microscopique

Perspectives




A.I.
Machine learning
Big Data

Le macroscopique



Evénements “rares”

Le microscopique



Merci...

...à toute l'équipe Hémato du LHUB-ULB